New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT05514132
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This early-stage study tests a new drug combination (ceralasertib plus durvalumab) in Chinese patients with advanced solid tumours that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see how the drugs move through the body. Only 14 patients will take part, and the study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100021, China
-
Research Site
Shandong, China
Conditions
Explore the condition pages connected to this study.